Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Geron Corp GERN

Alternate Symbol(s):  GERNW

Healthcare Biotechnology
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the... see more

Recent & Breaking News (NDAQ:GERN)

Geron Reports Oral Presentation at ASH Annual Meeting Highlighting Continuous Long-Term Transfusion Independence with Imetelstat Treatment in Lower Risk MDS Patients

Business Wire December 12, 2022

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire November 17, 2022

Geron to Participate in Stifel 2022 Healthcare Conference

Business Wire November 7, 2022

Geron Announces Presentations at Upcoming ASH Annual Meeting Including Long-term Phase 2 Data Showing Continuous Durable Transfusion Independence in Patients with Lower Risk MDS

Business Wire November 3, 2022

Geron Corporation Reports Third Quarter 2022 Financial Results and Upcoming Expected Milestones

Business Wire November 3, 2022

Geron to Announce Third Quarter 2022 Financial Results on November 3, 2022

Business Wire October 27, 2022

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire October 20, 2022

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire September 22, 2022

Geron Appoints Biopharma Veteran John F. McDonald to Board of Directors

Business Wire September 8, 2022

Geron to Present at Upcoming Investor Conferences

Business Wire September 1, 2022

Geron Announces First Patient Dosed in IMproveMF Phase 1 Combination Study in Frontline Myelofibrosis

Business Wire August 22, 2022

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire August 18, 2022

Geron Corporation Reports Second Quarter 2022 Financial Results

Business Wire August 11, 2022

Geron to Announce Second Quarter 2022 Financial Results on August 11, 2022

Business Wire August 4, 2022

Geron to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference

Business Wire August 3, 2022

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire July 21, 2022

Geron Corporation Announces Expansion of Existing Loan Facility

Business Wire June 30, 2022

Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire June 16, 2022

Geron Corporation Announces Appointment of Faye Feller, M.D. to Chief Medical Officer and Transition of Aleksandra Rizo, M.D., Ph.D. to Senior Advisor Role

Business Wire June 15, 2022

Lead Plaintiffs and Class Representatives Julia Junge and Richard Junge Announce Summary Notice of Pendency of Class Action (Nasdaq: GERN)

PR Newswire June 6, 2022